Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. MU
5. META
6. SPY
7. ACN
8. BLZE
9. IBM
10. NKE

Go back to Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Johnson & Johnson (NYSE: JNJ) Delayed: 239.08 --0 (-0%)
Previous Close $239.08    52 Week High $126.07 
Open $239.08    52 Week Low $94.28 
Day High $239.08    P/E 49.70 
Day Low $239.08    EPS $4.81 
Volume 1,573